Business Context and Reporting Period
This Form 6-K filing by Alvotech, dated December 17, 2025, covers a business update and a convertible bond offering. The company is a foreign private issuer based in Luxembourg, focusing on biosimilar development. The report details financial guidance for the fourth quarter of 2025 and the full year 2026, alongside the completion of a $108 million senior unsecured convertible bond offering.
Key Financial Metrics and Capital Structure
- 2025 Revenue Guidance: $570 million to $600 million (reaffirmed).
- 2025 Adjusted EBITDA Guidance: $130 million to $150 million.
- 2026 Revenue Guidance: $650 million to $700 million.
- 2026 Adjusted EBITDA Guidance: $180 million to $220 million.
- Convertible Bond Offering: $108 million senior unsecured convertible bonds due 2030.
- Bond Terms: 6.875% coupon, payable semi-annually; initial conversion price of $5.9224 per Swedish Depositary Receipt (SDR).
- Use of Proceeds: Investment in R&D pipeline, scaling, and product launches.
Note: The filing does not provide specific values for cash flow, debt levels prior to this offering, or liquidity ratios.
Material Changes and Operational Updates
- Regulatory Status: The company received a Complete Response Letter (CRL) from the FDA for AVT05 (biosimilars to Simponi and Simponi Aria) and AVT06 (biosimilar to Eylea). The guidance assumes a potential CRL for AVT03 (biosimilar to Prolia and Xgeva).
- Settlement Agreement: Alvotech and its U.S. commercial partner reached a settlement and license agreement with Regeneron Pharmaceuticals Inc. regarding AVT06.
- Launch Timeline: The agreement grants a license entry date for AVT06 in the U.S. in the fourth quarter of 2026, or potentially earlier if conditions are met.
- Revenue Assumptions: The 2026 guidance assumes minimal impact from new U.S. biosimilar launches on topline revenues for that year; the lower end of the revenue range excludes revenues from new U.S. launches.
Guidance, Outlook, and Risks
Management expects to receive FDA marketing approval for pending product candidates by late 2026, though this assumption may prove incorrect. The 2026 outlook incorporates the impact of potential further delays due to CRLs. The company utilizes Adjusted EBITDA as a non-IFRS measure to evaluate performance but notes that a quantitative reconciliation to the most directly comparable IFRS measure is not available without unreasonable effort at this time. Net income estimates are not provided due to the variability of excluded charges.
Risks and Contingencies:
- Uncertainty regarding FDA approval timelines for AVT03, AVT05, and AVT06.
- Potential delays in U.S. commercial launches affecting revenue realization.
- Forward-looking statements regarding the bond offering settlement and use of proceeds are subject to risks and uncertainties.
Investor Verification Checklist
- Verify the status of FDA applications for AVT03, AVT05, and AVT06 following the receipt of CRLs.
- Confirm the settlement date and final terms of the $108 million convertible bond offering.
- Monitor the specific conditions required to accelerate the AVT06 U.S. launch date prior to Q4 2026.
- Review the reconciliation of Adjusted EBITDA to IFRS net income in the next quarterly or annual report.
- Assess the impact of the 25% conversion premium on potential future equity dilution.